nivolumab,ipilimumab
bms
['ipi +', 'nivo', 'nsclc', ' ipi ', 'sclc', 'increase,(-increased)']
the increase trial by bahce et al evaluating preop chemort + ipi + nivo in 26 nsclc pts with limited mediastinal ln. impressive pcr=63%. 11% any grade pneumonitis. excellent discussion #esmo22 
Professor | Vice Chair of Clinical Research & Faculty Development | Thoracic & GI cancer researcher | Rutgers Cancer Institute of New Jersey | opinions my own